US009409966B2

(12) **United States Patent**
Spetzler et al.

(10) **Patent No.: US 9,409,966 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE**

(71) Applicant: **Novo Nordisk A/S**, Bagsvaerd (DK)

(72) Inventors: **Jane Spetzler**, Broenshoej (DK); **Lauge Schaeffer**, Lyngby (DK); **Jesper Lau**, Farum (DK); **Thomas Kruse**, Herlev (DK); **Patrick W. Garibay**, Holte (DK); **Steffen Reedtz-Runge**, Frederiksberg (DK); **Henning Thoegersen**, Farum (DK); **Ingrid Pettersson**, Frederiksberg (DK)

(73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 143 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/506,052**

(22) Filed: **Oct. 3, 2014**

(65) **Prior Publication Data**

US 2015/0025003 A1 Jan. 22, 2015

Related U.S. Application Data

(63) Continuation of application No. 12/676,451, filed as application No. PCT/EP2008/061755 on Sep. 5, 2008, now Pat. No. 8,895,694.

(60) Provisional application No. 60/971,930, filed on Sep. 13, 2007, provisional application No. 61/024,345, filed on Jan. 29, 2008.

(30) **Foreign Application Priority Data**

Sep. 5, 2007 (EP) 07115746
Jan. 28, 2008 (EP) 08101008

(51) **Int. Cl.**
C07K 14/605 (2006.01)
A61K 38/26 (2006.01)

(52) **U.S. Cl.**
CPC ***C07K 14/605*** (2013.01); ***A61K 38/26*** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,968,899	A	10/1999	Sekine et al.
6,268,343	B1	7/2001	Knudsen et al.
6,458,924	B2	10/2002	Knudsen et al.
7,235,627	B2	6/2007	Knudson et al.
7,271,149	B2	9/2007	Glaesner et al.
8,097,698	B2	1/2012	Knudsen et al.
8,895,694	B2	11/2014	Spetzler et al.
2001/0011071	A1	8/2001	Knudsen et al.
2007/0203058	A1	8/2007	Lau et al.

FOREIGN PATENT DOCUMENTS

EP	1364967	A2	11/2003
JP	05-506427		9/1993
JP	2001-504105	A	3/2001
JP	2006-520818	A	9/2006
WO	96/29342		9/1996
WO	9808871	A1	3/1998
WO	99/43708	A1	9/1999
WO	00/34331		6/2000
WO	00/69911		11/2000
WO	01/04156		1/2001
WO	02/46227	A2	6/2002
WO	03/011892	A2	2/2003
WO	2005/027978	A2	3/2005
WO	2005/058954	A1	6/2005
WO	2006/005667	A2	1/2006
WO	2006/037810		4/2006
WO	2006/097535	A2	9/2006
WO	2006/097536	A2	9/2006
WO	2006/097537	A2	9/2006
WO	2006/097538		9/2006

OTHER PUBLICATIONS

Runge et al., "Crystal Structure of the Ligand-Bound Glucagon-Like Peptide-1 Receptor Extracellular Domain," J Biol Chem 2008, vol. 283, No. 17, pp. 11340-11347.
Adelhorst, K et al Journal of Biological Chemistry Structure Activity Studies of GLP-1 1994 269 9 6275-6278.
Knudsen, L.B. Journal of Medicinal Chemistry Glucagon-Like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes 2004 47 17 4128-4134.
Leger et al., "Identification of CJC-1131-Albumin Bioconjugate as a Stable and Bioactive GLP-1 (7-36) Analog," Bioorganic and Medicinal Chemistry Letters, vol. 14, pp. 4395-4398 (2004).
Pan, 2006 Journal of Biological Chemistry vol. 281 pp. 12506-12515.
The Medical Dictionary Online. http://cancerweb.ncl.ac.uklomd/about.html. 2005.
Nauck, M A. Regulatory Peptides. "Glucagon-Like Peptide 1 and its Derivatives in the Treatment od Diabetes." 2005. vol. 128(2). pp. 135-148.
David M. Irwin, Trout and chicken Proglucagon: Alternative Splicing Generates mRNA Transcripts Encoding Glucagon-Like Peptide 2, Molecular Endocrinology, 1995, vol. 9 No. 3, 267-277.

Primary Examiner — Amber D Steele
Assistant Examiner — Schuyler Milton
(74) *Attorney, Agent, or Firm* — Richard W. Bork

(57) **ABSTRACT**

The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.

22 Claims, No Drawings